These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 34190962)

  • 1. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
    Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
    J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
    [No Abstract]   [Full Text] [Related]  

  • 3. Zuranolone for the Treatment of Postpartum Depression.
    Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
    Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
    Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
    Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Clayton AH; Lasser R; Nandy I; Sankoh AJ; Jonas J; Kanes SJ
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36811520
    [No Abstract]   [Full Text] [Related]  

  • 7. Trial of SAGE-217 in Patients with Major Depressive Disorder.
    Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
    N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
    Cutler AJ; Mattingly GW; Kornstein SG; Aaronson ST; Lasser R; Zhang H; Rana N; Brown C; Levin S; Miller C; Kotecha M; Forrestal F; Doherty J
    J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38153320
    [No Abstract]   [Full Text] [Related]  

  • 10. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
    Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
    J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
    Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
    Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
    Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
    J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
    Kato M; Nakagome K; Baba T; Sonoyama T; Okutsu D; Yamanaka H; Shimizu R; Motomiya T; Inoue T
    Psychiatry Clin Neurosci; 2023 Sep; 77(9):497-509. PubMed ID: 37252829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
    Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
    Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
    Zou J; Yang L; Yang G; Gao J
    Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
    Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
    Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.
    Epperson CN; Rubinow DR; Meltzer-Brody S; Deligiannidis KM; Riesenberg R; Krystal AD; Bankole K; Huang MY; Li H; Brown C; Kanes SJ; Lasser R
    J Affect Disord; 2023 Jan; 320():353-359. PubMed ID: 36191643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
    Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
    Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.